Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Orciuolo

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Recenti Progressi in Medicina|February 20, 2026
[CAR-T cell therapy in an elderly patient with DLBCL and early relapse (<12 months).]Enrico Orciuolo
Journal of Hematology & Oncology|June 22, 2018
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacyFederico Rossari, Filippo Minutolo, Enrico Orciuolo
Leukemia Research|October 19, 2006
Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitroEnrico Orciuolo, Sara Galimberti, Mario Petrini
British Journal of Haematology|November 19, 2009
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphomaEnrico Orciuolo, Gabriele Buda, Matteo Pelosini, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 9, 2019
Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implicationsFederico Rossari, Cristina Zucchinetti, Gabriele Buda, et al.
Lancet (London, England)|April 22, 2008
Folic acid fortification and cancer riskGabriele Buda, Enrico Orciuolo, Valentina Maggini, et al.
Leukemia Research|June 15, 2007
Association of PIM gene translocation and TEL/AML1 rearrangementGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Acta Haematologica|September 5, 2009
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myelomaGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Leukemia Research|November 23, 2006
Match unrelated bone marrow transplantation in a case of high risk myelodysplastic syndrome treated with azacitidine and concomitant 1alpha-25-dihydroxyvitamin D3, as differentiating agentEnrico Orciuolo, Nadia Cecconi, Sara Galimberti, et al.
Annals of Hematology|December 25, 2010
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patientsGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Recenti Progressi in Medicina|February 20, 2026
[CAR-T cell therapy in an elderly patient with DLBCL and early relapse (<12 months).]Enrico Orciuolo
Journal of Hematology & Oncology|June 22, 2018
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacyFederico Rossari, Filippo Minutolo, Enrico Orciuolo
Leukemia Research|October 19, 2006
Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitroEnrico Orciuolo, Sara Galimberti, Mario Petrini
British Journal of Haematology|November 19, 2009
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphomaEnrico Orciuolo, Gabriele Buda, Matteo Pelosini, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 9, 2019
Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implicationsFederico Rossari, Cristina Zucchinetti, Gabriele Buda, et al.
Lancet (London, England)|April 22, 2008
Folic acid fortification and cancer riskGabriele Buda, Enrico Orciuolo, Valentina Maggini, et al.
Leukemia Research|June 15, 2007
Association of PIM gene translocation and TEL/AML1 rearrangementGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Acta Haematologica|September 5, 2009
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myelomaGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Leukemia Research|November 23, 2006
Match unrelated bone marrow transplantation in a case of high risk myelodysplastic syndrome treated with azacitidine and concomitant 1alpha-25-dihydroxyvitamin D3, as differentiating agentEnrico Orciuolo, Nadia Cecconi, Sara Galimberti, et al.
Annals of Hematology|December 25, 2010
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patientsGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Pageof 8